<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01956305</url>
  </required_header>
  <id_info>
    <org_study_id>DS7309-A-U102</org_study_id>
    <nct_id>NCT01956305</nct_id>
  </id_info>
  <brief_title>Randomized, Placebo-controlled, 2 Period, Single-blind, Sequential, Multiple Ascending Dose Study</brief_title>
  <official_title>A Single Blind, (Subject and Investigator Blinded, Sponsor Unblinded), Two-Period, Placebo-Controlled, Randomized, Sequential, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DS 7309 In Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      DS-7309 is being developed for the treatment of type 2 diabetes mellitus (T2DM). This will be&#xD;
      a randomized, placebo-controlled, blinded, sequential, multiple ascending dose study to&#xD;
      assess the safety, tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of multiple&#xD;
      doses of DS-7309 in subjects with T2DM.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      DS-7309 is being developed for the treatment of type 2 diabetes mellitus (T2DM). This will be&#xD;
      a randomized, placebo-controlled, single-blind (subject and investigator-blinded,&#xD;
      sponsor-unblinded), sequential, multiple ascending dose study to assess the safety,&#xD;
      tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) of multiple doses of DS-7309 in&#xD;
      subjects with T2DM. The safety and tolerability of each new dose level will be tested in a&#xD;
      single day administration prior to start of repeated dosing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety and tolerability of DS-7309</measure>
    <time_frame>23 days, Day -7 through Day 16</time_frame>
    <description>number, type and severity of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>determine the pharmacokinetics of DS-7309 after repeated doses</measure>
    <time_frame>23 days, Day-7 through Day 16</time_frame>
    <description>Cmax, Tmax, area under the concentration curve (AUC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>determine glycemic response</measure>
    <time_frame>23 days, Day -7 through Day 16</time_frame>
    <description>glycemic response will be assessed by blood sampling for plasma glucose after a meal tolerance test and from 24h weighted mean glucose on Day -1 and Day 12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the effects of repeated doses of DS-7309 on plasma insulin levels in T2DM subjects</measure>
    <time_frame>23 days, Day -7 through Day 16</time_frame>
    <description>To assess the effects of repeated doses of DS-7309 on plasma insulin levels in T2DM subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the effects of repeated doses of DS-7309 on blood pressure</measure>
    <time_frame>23 days, Day -7 through Day 16</time_frame>
    <description>To assess the effects of repeated doses of DS-7309 on blood pressure (by means of 24 h ambulatory blood pressure measurements (ABPMs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the effects of repeated doses of DS-7309 on lipid profile</measure>
    <time_frame>23 days, Day -7 through Day 16</time_frame>
    <description>To assess the effects of repeated doses of DS-7309 on lipid profile (total, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) cholesterol and triglycerides)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the effects of repeated doses of DS-7309 on plasma lactate levels</measure>
    <time_frame>23 days; Day -7 through Day 16</time_frame>
    <description>To assess the effects of repeated doses of DS-7309 on plasma lactate levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the effects of repeated doses of DS-7309 on C-peptide levels in T2DM subjects</measure>
    <time_frame>23 days, Day -7 through Day 16</time_frame>
    <description>To assess the effects of repeated doses of DS-7309 on C-peptide levels in T2DM subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the effects of repeated doses of DS-7309 on glucagon levels in T2DM subjects</measure>
    <time_frame>23 days, Day -7 through Day 16</time_frame>
    <description>To assess the effects of repeated doses of DS-7309 on glucagon levels in T2DM subjects</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Cohort A 10mg DS-7309</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DS-7309 10 mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B 20mg DS-7309</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DS-7309 20 mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C DS-7309 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DS-7309 40 mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort D DS-7309 75 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DS-7309 75 mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort E DS-7309 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DS-7309 150 mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort F DS-7309 150 mg with escalating metformin doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DS-7309 150 mg twice daily with escalating metformin doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo to match DS-7309</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DS-7309</intervention_name>
    <description>DS-7309 powder in bottle</description>
    <arm_group_label>Cohort A 10mg DS-7309</arm_group_label>
    <arm_group_label>Cohort B 20mg DS-7309</arm_group_label>
    <arm_group_label>Cohort C DS-7309 40 mg</arm_group_label>
    <arm_group_label>Cohort D DS-7309 75 mg</arm_group_label>
    <arm_group_label>Cohort E DS-7309 150 mg</arm_group_label>
    <arm_group_label>Cohort F DS-7309 150 mg with escalating metformin doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo to match DS-7309 powder in bottle</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin 500mg tablet for Cohort F</description>
    <arm_group_label>Cohort F DS-7309 150 mg with escalating metformin doses</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female volunteers aged 18 to 65 years, inclusive.&#xD;
&#xD;
          -  Male subjects have to agree to contraception (condom with spermicide) in addition to&#xD;
             having their female partner (if of child-bearing potential) use another form of&#xD;
             contraception&#xD;
&#xD;
          -  Women must be of non-childbearing potential&#xD;
&#xD;
          -  Diagnosed with T2DM for at least 3 months prior to first dose.&#xD;
&#xD;
          -  Subjects must be either:&#xD;
&#xD;
        On monotherapy with either metformin or a DPP-IV inhibitor alone with a HbA1c between 6.5%&#xD;
        to 9.5%, inclusive, and willing to discontinue current metformin or DPP-IV inhibitor&#xD;
        treatment for at least 2 weeks prior to check in and until discharge from the clinic (for&#xD;
        Cohorts A to E). OR Treatment naive from any anti-diabetes mellitus drugs for at least 3&#xD;
        months prior to Screening with an HbA1c between 7% to 10%, inclusive.&#xD;
&#xD;
          -  Fasting plasma glucose ≥100 mg/dL and ≤250 mg/dL at Screening.&#xD;
&#xD;
          -  Fasting plasma glucose ≥120 mg/dL and ≤250 mg/dL on Day -6.&#xD;
&#xD;
          -  All women must have a negative serum pregnancy test at Screening and within 2 days&#xD;
             before dosing.&#xD;
&#xD;
          -  A BMI of 19 to 36 kg/m2 inclusive; or, if outside the range, not clinically&#xD;
             significant and agreed upon by DSPD or the CRO and the Investigator.&#xD;
&#xD;
          -  Good health as determined by the absence of clinically significant deviations from&#xD;
             normal, based on medical history, physical examination, laboratory reports, and&#xD;
             triplicate 12-lead ECG (except for findings associated with T2DM), as deemed by the&#xD;
             Investigator, prior to enrollment.&#xD;
&#xD;
          -  Has given written informed consent prior to participating in the study.&#xD;
&#xD;
          -  Able to understand and willing to comply with all study requirements, and willing to&#xD;
             allow the collection of all blood and urine specimens.&#xD;
&#xD;
          -  Negative urine test for drugs of abuse (opiates, benzodiazepines, amphetamines,&#xD;
             cannabinoids, cocaine, barbiturates, phencyclidine), cotinine, and alcohol at&#xD;
             Screening.&#xD;
&#xD;
          -  Negative result for HIV antibody hepatitis B surface antigen, and hepatitis C antibody&#xD;
             at Screening.&#xD;
&#xD;
          -  Willing to abstain from grapefruit/grapefruit juice and Seville oranges from 10 days&#xD;
             before the first dose and throughout the study.&#xD;
&#xD;
          -  Willing to refrain from consuming food or beverages containing caffeine/xanthine&#xD;
             starting 24 hours prior to check-in.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of type 1 diabetes and/or history of diabetic ketoacidosis.&#xD;
&#xD;
          -  History or clinical and laboratory evidence of significant complications of T2DM,&#xD;
             including proliferative retinopathy, macroalbuminuria, peripheral neuropathy, ischemic&#xD;
             heart disease, stroke, and peripheral vascular disease.&#xD;
&#xD;
          -  Screening laboratory values outside the range of normal values and deemed clinically&#xD;
             significant by the Investigator. Liver function tests (AST, ALT, total bilirubin) and&#xD;
             lactate dehydrogenase must be at or below 1.5 times ULN. If a subject has a&#xD;
             non-clinically significant high abnormal reading for 1 or more of the liver function&#xD;
             test results that are at or below 1.5 times ULN on the repeat test, the subject may be&#xD;
             enrolled provided the results from the laboratory tests performed on the day after&#xD;
             check-in are also at or below 1.5 times ULN.&#xD;
&#xD;
          -  Estimated glomerular filtration rate (eGFR) &lt;80 mL/min.&#xD;
&#xD;
          -  Any history of drug abuse.&#xD;
&#xD;
          -  History of alcohol addiction during the 2 years prior to Screening.&#xD;
&#xD;
          -  History of significant allergic response to any drug except penicillin.&#xD;
&#xD;
          -  History or current evidence, as determined by the Investigator, of psychiatric or&#xD;
             emotional problems that would invalidate giving informed consent or limit the ability&#xD;
             of the subject to comply with study requirements.&#xD;
&#xD;
          -  History or current evidence of clinically significant cardiac, hepatic, renal,&#xD;
             urinary, pulmonary, endocrine, neurologic, infectious, gastrointestinal, hematologic,&#xD;
             or oncologic disease as determined by the Investigator.&#xD;
&#xD;
          -  Subjects with a history of congenital long QT syndrome, a history of surviving a&#xD;
             near-drowning episode, or a history of unexplained syncope or loss of consciousness.&#xD;
&#xD;
          -  Subjects with QTcF interval duration &gt; 450 msec obtained as an average from the ECG&#xD;
             machine readings on the triplicate ECG taken at Screening.&#xD;
&#xD;
          -  Subjects with abnormal ECG waveform morphology on any of the ECGs from the screening&#xD;
             triplicate that would preclude accurate manual measurement of the QT interval&#xD;
             duration.&#xD;
&#xD;
          -  Hemoglobin &lt; 12.0 g/dL at Screening.&#xD;
&#xD;
          -  Need for any concomitant medication except for those specified Consumption of foods or&#xD;
             beverages containing alcohol from 24 hours before check-in through discharge from the&#xD;
             clinic.&#xD;
&#xD;
          -  Blood donation of 500 mL or more or significant blood loss within the 56 days before&#xD;
             check-in.&#xD;
&#xD;
          -  Plasma donation within 7 days before check-in.&#xD;
&#xD;
          -  Participation in another investigational new drug research study within the 30 days&#xD;
             before check-in.&#xD;
&#xD;
          -  Use of tobacco products or nicotine-containing products (including smoking cessation&#xD;
             aids, such as gums or patches) within the 6 months before check-in.&#xD;
&#xD;
          -  Relationship of the subject to the Investigator, any sub-Investigator, pharmacist,&#xD;
             study coordinator, or other staff directly involved in the conduct of the study, or&#xD;
             employment by DSPD or the CRO participating in the study.&#xD;
&#xD;
          -  Familial relationship of the subject to any subjects previously or currently enrolled&#xD;
             in the study.&#xD;
&#xD;
          -  Enrollment in a prior dose cohort of this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Worldwide Clinical Trials</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <study_first_submitted>September 30, 2013</study_first_submitted>
  <study_first_submitted_qc>October 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2013</study_first_posted>
  <last_update_submitted>November 20, 2014</last_update_submitted>
  <last_update_submitted_qc>November 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

